Innate Pharma (IPHA) Total Non-Current Liabilities (2017 - 2025)

Innate Pharma (IPHA) has 9 years of Total Non-Current Liabilities data on file, last reported at $55.6 million in Q4 2025.

• Quarterly Total Non-Current Liabilities fell 24.84% year-over-year to $55.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $55.6 million (down 24.84% YoY) and the FY2025 annual result came in at $55.6 million, down 24.84% from the prior year.
• Total Non-Current Liabilities fell to $55.6 million in Q4 2025, from $66.1 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $112.7 million in Q2 2023 to a low of $55.6 million in Q4 2025.
• A 5-year average of $89.2 million and a median of $91.3 million in 2021 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2021 — Total Non-Current Liabilities slumped 99.75% — and 2023, when it rose 16.68%.
• Tracing IPHA's Total Non-Current Liabilities over 5 years: stood at $91.7 million in 2021, then climbed by 15.48% to $105.9 million in 2022, then decreased by 15.02% to $90.0 million in 2023, then retreated by 17.79% to $74.0 million in 2024, then declined by 24.84% to $55.6 million in 2025.
• The last three Total Non-Current Liabilities figures came in at $55.6 million (Q4 2025), $66.1 million (Q2 2025), and $74.0 million (Q4 2024), per Business Quant data.